Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6893

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6893). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve showing the proportion of patients with relapse over time in days from randomization, comparing Duloxetine treatment and placebo groups. The graph plots relapse proportion on the vertical axis and time in days on the horizontal axis, illustrating differences in relapse rates between the two treatments over approximately 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily and Placebo. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. The graph shows a higher percentage of patient improvement with Duloxetine compared to placebo as pain improvement increases.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between Duloxetine and placebo treatments. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. Two lines depict relapse rates: a dashed line for placebo and a solid line for Duloxetine, with placebo showing higher relapse proportions over time.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine in doses of 60 mg twice daily, 60 mg once daily, 20 mg once daily, and placebo. The graph plots the relationship between pain improvement and patient response rates for these different dosage regimens.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis represents percent improvement in pain, and the y-axis represents percentage of patients improved, with data points plotted for each group across the improvement spectrum.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, once daily, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%). Three lines depict the patient improvement trends for each treatment group over the pain improvement range.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients who improved based on the percent improvement in pain from baseline. The graph compares Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily with a placebo group, illustrating patient improvement trends across different pain reduction thresholds.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph depicting the percentage of patients improved in pain from baseline for Duloxetine 60 mg once daily compared to placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. Two lines show that Duloxetine has consistently higher patient improvement percentages across pain improvement levels than placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The graph shows two curves, one marked with diamonds for Duloxetine and one with crosses for placebo, plotted over a range of pain improvement percentages from greater than 0 to 100%.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain, the y-axis shows percentage of patients improved. Duloxetine data points are marked with solid diamonds and placebo with crosses.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure illustration of duloxetine hydrochloride, showing the substitution pattern on the naphthalene and thiophene rings with the chiral center and hydrochloride salt form.*

FDA Label Image

Label Image (Lbl500906893)

Label for Duloxetine 60 mg delayed-release capsules by A-S Medication Solutions. The label states each capsule contains enteric-coated pellets equivalent to 60 mg of duloxetine. It directs storage at 77 degrees Fahrenheit and indicates a quantity of 90 capsules in the package. Additional labeling includes NDC 50090-6893-0 and manufacturing information from Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.